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This article continues the review begun in a previous issue of the
Journal, which considered the molecular basis and epidemiology of
thrombophilia.
Laboratory Investigation of Inherited Thrombophilia
What Laboratory Assays Should be Included?
In order to evaluate the contribution of genetic defects in the patho-
genesis of thrombosis, the laboratory investigation should include a
functional APC-R lest, determination of the factor V genotype and
measurements of plasma concentrations of PC, PS (total and free PS)
and antithrorabin. In addition, a thrombin time will ensure that rare
cases of dysfibrinogenemia are not overlooked. At present, available
results suggest fibrinolytic parameters not to be of value in the evalua-
tion of individual patients (2).
Before selecting the analytical procedure in the laboratory a number
of questions should be addressed such äs what are the sensitivity and
specificity of the laboratory assay for the genetic defect to be detected?
Moreover, the assay performance such äs inter- and intra-day Variation
are important factors to take into account. Quality control should be of
high priority. In the choice of assay it is cracial to consider possible
influence by other defects, e.g. APC-R influence on coagulation-based
functional assays for PC and PS (see below). An important parameter to
be taken into consideration is the predictive value of a positive and a
negative lest. This is determined not only by the specificity and sensi-
tivity of the assay but also by the prevalence in the population to be
studied for the particular defect. Thus, unless the specificity is close to
100%, the predictive value of a positive lest is usually quite low for
defects which are rare in the population. Examples of this will be given
below.
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Anticoagulant Protein Deficiencies
A detailed evaluation of the possible contribution of anticoagulant
protein deficiencies in the pathogenesis of thrombosis should include
analysis of both protein levels with immunological assays and of the
functional activity of each of these proteins. However, this is not
always possible and practical compromises have to be made. In gener-
al, deficiencies of type I (low protein concentration) of any of the anti-
coagulant proteins are much more common than type Π deficiencies
(low functional activity but normal protein concentration). An optimal
assay for each of these proteins is an easy and cheap functional assay
which detects both type I and type II deficiencies. In the case of anti-
thrombin, there are several commercially available functional assays
(based on Inhibition of either thrombin or factor Xa) which fulfill these
criteria. An International Standard for antithrombin is available.
The Situation for PC and PS is more complicated because the avail-
able coagulation based functional assays are complicated to perform
and several of them have low sensitivity and specificity. Assays
devised to measure the protein concentrations are often cheaper and
easier to perform than several of the commercially available functional
assays, and consequently such assays are used in most laboratories in
the primary evaluation of the patients. Both sensitivity and specificity
of immunological äs well äs of functional assays are lower when used
to lest individuals on oral anticoagulation than when used to test
patients without anticoagulant therapy.
In the case of PC, depending on the site of the mutation there are
many different possible types of functional defects. The interaction
with the thrombin-thrombomodulin complex may for instance be
impaired with a resulting poor activation; mutations in the vitamin
K-dependent region may lead to poor phospholipid binding ability;
mutations in other parts of PC may lead to functional defects due to
poor interactions with either Substrates or cofactors. There is at present
no easily available functional assay which monitors all functional
aspects of PC and consequently, the laboratory evaluation is a practical
compromise. A functional, easy, assay is available for PC and it is used
in many laboratories äs an alternative to immunological assays in the
primary screening of the thrombosis patients. The assay includes acti-
vation of PC in plasma with a PC activator (Protac) isolated from a
snake venom and measurement of the proteolytic activity of the activat-
ed PC against a synthetic Substrate. The assay, which is readily auto-
mated, is available from several commercial sources. It shouid be borne
in mind that the assay does not detect several of the type II detects. As
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there is an overlap m the PC concentrations between normals and those
with the genetic defects (3), sensitivity and specificity of all available
functional or immunological assays for the genetic defects causmg PC
deficiency are below 100% The Protac based assays perform quite well
and have coefficients of Variation below 2% The sensitivity has been
estimated to be 85%, whereas the specificity is estimated to be 95% (3)
When this assay is used to study a population m which the prevalence
is around 0 3%, the predictive value of a positive test is 5% whereas the
predictive value of a negative test 99 9% Thus, m screenmg of the
general population this assay is excellent to exclude PC deficiency,
whereas a positive test is caused by a genetic defect m only 5% of the
cases When the assay is used to test patients with thrombosis (preva-
lence of genetic defect approximately 3%), the predictive value of a
negative test is 34% whereas the predictive value to a positive test is
99 6% The predictive value of a positive test is negatively related to the
PC level, t e the lower the PC level the higher the predictive value
There is an International Standard for PC available
At present, there are no functional PS assays which fulfill the
requirements that can be put on an assay which is to be used m the
pnmary evaluation of thrombosis patients The low specificity of the
available functional assays is a major problem äs it has recently been
shown that functional assays for PS are mfluenced by the APC-R asso-
ciated with the presence of the factor V 506Arg to Gin mutation (4) As
PS circulates m plasma both äs free protem (approximately 30%) and in
complex with the C4b-bmdmg protem (5), a relevant question is which
fraction of PS should be measured with the immunological assays, the
free form, the bound form or total PS The current provisional conclu-
sion is that the free PS assays have higher sensitivity and specificity for
the genetic defects causmg PS deficiencies than assays for total PS
This is because there is a great overlap m the total PS levels between
normals and those with the genetic defect (6) Although the prevalence
of PS deficiency m the general population is not well estabhshed it is
reasonable to suspect that it is sirmlar to that of PC and the discussion
about the predictive value for a negative and positive test (see above) is
therefore relevant also for PS There are several commercially available
assays for both free and total PS and an International Standard will
become available
The APC-R Test
So far, practical chmcal expenence has mamly been obtamed with
the APTT-based test for APC-R (7) In an APTT reaction, the addition
of APC results m degradation of both factor Villa and factor Va, which
delays thrombin generation and hence the formation of the fibnn
clot The factor V 506Arg to Gin mutation is associated with partial
resistance to degradation of mutated factor Va by APC but the
mutated factor Va expresses normal procoagulant properties (8-10)
Consequently, thrombin generation is not properly impaired m the pres-
ence of APC, which results m less Prolongation of the clottmg time
As the APC-R test is based on a Standard APTT-reaction it is easy to
perform The APTT-reaction is run m the presence and absence of a
carefully standardised amount of APC, which is mcluded in the calcium
chlonde solution used to mitiate the clottmg reaction (7) The clottmg
time is measured m the presence (a) and absence (b) of APC and a ratio
(the APC-raüo) between the two clottmg times (a/b) is calculated If the
assay is always done on the same Instrument and also m other respects
performed under stnctly standardised conditions, the resultmg APC-
ratios can be used äs they are (l l, 12) However, it has been observed
that different Instruments give different clottmg times and APC-ratios
obtamed on one type of Instrument cannot be directly compared with
those from another type (13) If results from different laboratones are
to be compared, it is beneficial to normahse the APC-ratios agamst
the APC-ratio of a normal plasma pool (14) There are some nnportant
considerations to take mto account m relation to such a normalisation
procedure Due to the high prevalence of APC-R m the general popula-
tion a pool of normal plasmas is fairly hkely to contam plasma from
mdividuals with APC-R and m accordance with this, it has mdeed been
found that APC-ratios of normal plasma pools are always lower than
the mean of the mdividual APC-ratios For laboratones not havmg the
possibihty to perform factor V genotypmg, a practical solution to the
problem may be to exclude plasmas with extreme APC-ratios from the
pool. eg the 5 or 10% with the highest and the 5 or 10% with the
lowest APC-ratios In this context, it is obvious that an International
Standard plasma would be useful
The handlmg of the plasma samples is probably of importance and
the quahty of the results depend on stnct standardisaüon The centnfu-
gation of blood should ensure that the resultmg plasma is platelet poor
(<1% of normal platelet count), because e\en a small contammation ot
platelets affects the APC-ratio, m particular after freezmg and thawmg
of the plasma, platelet contammation will lower the APC-ratio (15) For
routme purposes it is recommended to centnfuge the plasma at 2000 g
for 20 mm at room temperature When the plasma is pipetted off, only
the middle portion should preferably be utilised to avoid platelet
contammation by native or disrupted platelets
The APC-R test can be performed on both fresh and frozen plasma
but "like should be compared with like", i e \vhen fresh plasma is ana-
lysed, the normal ränge should have been determmed with fresh plas
ma, when samples are frozen at -70° C or at -20° C they should be
compared with normal controls handled in the same way In suppoit foi
this concept, it was recently reported that freezmg of plasma results m
decreased APC-R (Coatest® APC™ Resistance from Chromogemx
Molndal, Sweden, was used m the study) but of practical impoitance
the authors found no differences between freezmg tempeiatures
(-70° C and -30° C tested) (14) When all variables are stnctly con-
trolled, the APC-R test is rehable and gi\es good discnmination
between normal and APC-R mdividuals The reported sensitivity and
specificity of the APC-R test for factor V 506Arg to Gin aie 85-95% or
better Variation m endogenous levels of PC has of couise, no mflu-
ence on the APC-R because a standardised amount of APC is added In
addition, Variation of the endogenous free PS level withm the ränge
expected for heterozygous PS deficiency and normals has no or only a
very mmor mfluence on the APC response m the APTT-based assay
(7,14)
The original APC-R test has a sensiti\ it\ of 94% tor detection of
factor V 506 Gin allele, whereas the specificin is approximately 85%
(sirmlar results have been found foi the commercial assay from Chi omo-
gemx) If this test is used for scieenmg ot a population m which the
prevalence is around 10%, the negative predictive value is 99 7%
whereas the positive predictive value is onh 16% In screenmg a popu-
lation with thrombosis the negative predicme \dlue is 97% whereas
the positive predictive value is around 73% Thus a positive test should
always be confirmed by factor V genonpmg The sensitivity and
specificity of the APC-R test appears to be lelated to the quahty of the
APTT reagent
The original APC-R test is not lehable tor analvsis ot plasmas hom
mdividuals receivmg oral anticoagulants or hepann 01 it they are
denved from mdividuals with other coagulation detects such äs lupus
anticoagulants or coagulation factor dehcienues ( 1 1 14) In plasma
from patients on oral vitamm K antagomsts the dottmg times m the
presence of APC are usually quite long (clottmg mav not even occur m
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such plasmas), which results in high ratios In order to allow analysis of
such plasmas, a modified APC-R test, m which sample plasma is
prediluted with factor V deficient plasma before assay, was suggested
(16-18) A predüution of l m 4 of sample plasma with factor V
deficient plasma seems to provide sufficient amounts of Vitamin
K-dependent coagulation factors in the assay to yield normal basal
APTT This modification gives vahd results not only for patients on
oral anticoagulation but has been found also to provide an improved
discnmmation for the factor V 506 Arg to Gin mutation For some time
this modification has been evaluated, usmg plasmas from mdividuals
with or without oral anticoagulant therapy and a 100% sensitivity and
speciftcity for the presence ot the factor V 506 Gin allele was obtamed,
irrespective of the plasma origm Thus, the modified test is an excellent
screenmg test for the presence of the factor V 506 Gin allele
Analysis for the Factor V 506Ar g to Gin Mutation
The codon for Arg506 is positioned close to the exon-mtron
boundary in exon 10ofthefactorVgene(19) Determination ot the G to
A mutation mvolves amphfication of this nucleotide region eithei from
genomic DNA or from mRNA The detection of the point mutation can
be made m many ways, e g by nucleotide sequencmg, by different
hybndisation techniques, by restnction enzyme cleavage or by allele
specific amplification (20-25) The methodology can be optirmsed to
allow analysis of a large number of samples every day The rate limit-
mg step is usually the preparation of patient DNA, even though rather
simple extraction procedures can be used It is important to recogmse
the nsk of contammation of PCR-based assay s and hence it is of utmost
importance to orgamse the work carefully and include both positive and
negative controls
The APC-R Test vet ms the Factor V Gene Mutation Test
Optimal evaluation of a smgle patient requires both the functional
APC-R test and the factor V gene mutation analysis to be used, because
the two methods provide complementary Information However, for
economical and practical reasons it will not always be possible to do
both tests on all mdividuals Until more expenence is obtamed by
mdividual mvestigators it seems that a rational approach would be to
perform parallel APC-R tests m the absence and presence of factor V
deficient plasma until confidence is obtamed with the latter Apart fiom
allowmg analysis of plasma from mdividuals on oral anticoagulant
therapy, this approach will also decrease the need foi confirmatory
genetic testine
the other genetic defects are less mteresting to evaluate for prophylac-
tic screenmg are the relatively low levels of sensitivity and specificity
which gives low predictive value of a positive test Cost-benefit
analysis are required m the evaluation of prophylactic testmg
To date it has not been recommended to perform the laboratorv
mvestigation m association with the acute thrombotic event mainly
because most assays are difficult to Interpret and the therapeutic
regimes may mfluence the results of the assays This recommendation
may need to be re-evaluated with the availabihty of the modified
highly specific and sensitive APC-R test (with factor V deticient plas-
ma) and factor V genotypmg
Wheie Should the Laboiatoi~\ [nvestigatwn be Perfouned7
The specialised assays for anticoagulant protem deficiencies are
prefeiably performed m specialised coagulation umts whereas it is a
matter of debate where the APC-R testmg should be done Time will
give the APC-R testmg its nght role m practical medicme and it will at
this stage become obvious whether the testmg should be periormed not
only m specialised laboratories but also m major or smaller hospitals
Who Should be Tested?
This question is related to the questions what to test and why It is
recommendable that testmg is performed on patients with thrombosis
and possibly also on their first degree family members It is vahd to
conclude that theie aie at piesent no data to support general screenmg
of the population for APC-R Whether prophylactic APC-R testmg is
beneficial m association with nsk situations is yet to be evaluated
Whv Should We Test for Genetic Defects Piedisposmg
fot Thrombosis'
For each category of mdividuals it is impoitant to ask the question
why the testmg is performed The most pertment question is whether
the results of the assays will affect the handlmg of the patients This is
true for both general screenmg and for mvestigation of thrombosis
patients The lapid expansion of knowledge m this field will bring ne\v
therapeutic lecommendations for mdividuals with genetic predisposi-
tion for thrombosis There are two major leasons for testmg of farmh
members of patients with thrombosis the prophylactic and diagnostic
purposes The prophylactic aspects lelate to the possibilities to give
adequate advice to family members and the diagnostic purposes to
make rehable diasnosis of mhented delects
When Is itAppropnate to Perfotm the Laboratorv Evaluation7
At present most testmg is performed after a thrombotic episode and
also after discontmuation ot the oral anticoagulation Most of the assays
have their highest sensitivity and specificity for the genetic defects if
this is stnctly followed Testmg for PC and PS is not rehable durmg oral
anticoagulation and it is pieterable that the patient has been otf this kmd
ot therapy for at least 10 days In raie cases it is possible to discontmue
the therapy for 10 days dm mg which the patient receives heparm (Stan-
dard or low molecular weight hepann) A sample can be drawn on the
mornmg ot the tenth day betöre the hepann admimstration
It will be mteresting to evaluate whether piophylattic testmg ot
APC-R betöre surgeiy oral contraception, hospitahsation will be
beneticial Highly sensitive and specific assays for APC-R with high
piedictive value aie available and mexpensive The mam leasons why
Clinical Manifestations of Inhented Thrombosis
The most common climcal problem is deep vein thrombosis of the
lower hmbs, with 01 without pulmonarv embohsm, accountmg for
approximately 90% of all the thrombotic episodes, Table l Unusual
sites ot venous thrombosis, such äs those m the mesentenc or cerebral
vems, account tor less than 5% of the total episodes in patients with
antithiorabm PC 01 PS deficiencies m patients with APC-R thrombo-
sis seems to occur less tiequently at these sites Supeihcial thiombo-
phlebitis is moie trequent m patients with PC or PS dehciency and
APC R than m antithiombm deficient patients Even though a t öle foi
PS deliciency äs a nsk tactoi tor artenal thiombosis has been postulat-
ed, there is little current evidence that this or other heterozygous
detects ot the antiooagulant Systems increase the nsk öl artenal throm-
bosis (28, 29)
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Table l Clmical features of patients with inhented thrombophiha due
to defects m the anticoagulant pathways
Venous thromboembohsm (>90% of cases)
- Deep vem thrombosis of lower hmbs (common)
- Pulmonary embolism (common)
- Superficial thrombophlebitis
- Mesentenc vem thrombosis (rare but charactenstic)
- Cerebral vem thrombosis (rare but charactenstic)
Family history of thrombosis*
First thrombosis usually at young age (<45 yrs )x
Frequent recurrences*
Neonatal purpura fulmmans
(homozygous protein C and protein S deficiency)
- All these features are less evident m patients with APC-R, who
appear to be less severely affected climcally
There is history of thrombosis at diagnosis m 50-60% of mdividuals
with antithrombm, PC and PS deficiencies, with a 50% recurrence rate,
the first thrombotic episode occurs äs early äs before 40 years in
approximately 80% of patients In antithrombm deficiency, the Overall
nsk of venous thrombosis is considered greater than m PC or PS
deficiency (30), but contradictory results have been obtamed (29) On
the other hand, mdividuals with APC-R appear to have a lesser tenden-
cy to thrombosis than those with the defects of the naturally occumng
anticoagulants There is history of thrombosis m only 23% to 31% of
cases with APC-R (l l, 24) and only 30% of them develop thrombosis
before age 45 (31) The presence of APC-R however magmfies the nsk
of thrombosis m patients with antithrombm, PC and PS deficiencies
(32-34), äs discussed earlier
In antithrombm, PC and PS deficiencies 32% to 50% of the venous
thrombotic episodes occur when other nsk factors are concomitantly
present (surgery, pregnancy, immobihzation) (26-29) In mdividuals
with APC-R, the need of the existence of such nsk factors to tngger
thrombotic episodes appears to be greater (62%) than for the other
thrombophilic syndromes (24)
The nsk factors that are more often associated with the occurrence of
thrombosis are pregnancy, the puerpenum and surgery (24,26,27,29)
In women with antithrombm deficiency, the frequency of thrombosis
dunng pregnancy and the puerpenum is between 37% and 44%, m PC
or PS deficiency, between 12% and 19% (35,36), m APC-R, 28% (37)
Thrombotic episodes occur most frequently during the puerpenum,
accounting for 60-75% of all the episodes comphcating pregnancy (35,
36) A retrospective analysis of a large number of antithrombm, PC or
PS deficient mdividuals gave an overall frequency of venous thrombo-
sis comphcating surgery of 22%, with no sigmficant differences due to
the type of deficiency or surgical procedure (36) Intake of oral contra-
ceptives is associated with an mcreased thrombotic nsk, parücularly m
women with antithrombm deticiency and APC-R (38, 39) Patients
with dysfunctional defects of antithrombm, PC and PS have thrombot-
ic nsks similai to those of the correspondmg quantitative defects
A notable exception is the antithrombm HBS type II subtype, with a
prevalence ot thrombosis m these (heterozygous) cases of only 6%,
contrasting with 52-68% m patients with other types of antithrombm
deficiencies (40)
Homozygous antithrombm deficiency is extremely rare and almost
exclusively reported m patients with HBS defects These mdividuals
have a severe thrombotic history of early onset, often affecting artenes
(41) Homozygous type I antithrombin deficiency is, presumably, m-
compaüble with hfe in one report, two brothers with this defect died
withm three weeks of birth (42) Homozygous PC deficiency has pecu-
har phenotypic and chnical expressions [reviewed m (43)] In patients
with unmeasurable PC, purpura fulmmans. due to thrombosis of small
vessels with cutaneous and subcutaneous ischemic necrosis, may occur
soon after birth or m the first year of hfe (44,45) In patients with very
low but measurable PC (5-20%), chnical mamfestations are milder and
generally similar to those for heterozygous deficiency (46) Homo-
zygous PS deficiency has been rarely reported, but is also associated
with neonatal purpura fulmmans (47) Due to the high frequency of the
mutant factor V m the general population, homozygous APC-R is
relatively frequent, ~1 5000(48) Whether homozygotes have a nsk of
artenal thrombosis greater than that of the general population remams
to be elucidated (49,50)
Management of Inhented Thrombophilia
Acute Events
The management of acute venous thrombosis or pulmonary embo-
lism m patients with inhented thrombophiha is generally not different
from other patients Thrombolytic therapy can be used m patients with
massive acute venous thrombosis or pulmonary embolism Hepann
should be mitiated with an intravenous bolus of 5,000 umts followed by
an mfusion of 1400 umts per hour (51), or if a weight adjusted regimen
is used, a bolus of 80 umts per kg body weight followed by an mfusion
of 18 umts per kg per hour (52) The APTT should be performed
approximately 6 hours after therapy is mitiated and at least daily there-
after to mamtam the clotting time in the therapeutic ränge For many
commercial APTT reagents, this conesponds to an APTT that is l 8 to
3 0 times the mean of the noimal ränge or an anti-factor Xa heparm
level of 0 3 to 0 7 umts per ml (53) For less sensitive APTT reagents,
the therapeutic APPT ratio is l 5 to 2 0 (54) Warfarm can be started
withm the first 24 h Heparm is contmued for at least 5 days (55) or
until the prothrombm time is m the therapeutic ränge, namely an Inter-
national Normahzed Ratio (INR) of 2 0 to 3 0
Patients with antithrombm deficiency can usually be treated success-
fully with intravenous heparm (56), though m some situations unu-
sually high doses of the drug are required to achieve adequate anticoag-
ulation In antithrombm deficient patients receiving heparm for the
treatment of acute thrombosis, the adjunctue role of antithrombm
concentrate punfied from human plasma is not clearly defmed, äs
controlled tnals have not been performed (56) This product should
probably be admimstered when difficulty is encountered m achievmg
adequate heparmization, or recurrent thrombosis is observed despite
adequate anticoagulation It is also reasonable to treat antithrombm
deficient subjects with concentrate before major surgenes or m ob-
stetncal situations where the nsks of bleedmg from anticoagulation are
unacceptable The manufactunng processes used to prepare antithrom-
bm concentrate result m a product that is greater than 95% pure, they
also mactivate the hepatitis B and C viruses and human immuno-
dehciency virus I (57 58) Hence, it is preterable to admimster anti-
thrombin concentrate rather than tresh trozen plasma
The mfusion ot 50 umts of antithrombm concentrate per kilogram
ot body weight (one umt is defmed äs the amount ot antithrombm m
one ml of pooled noimal human plasma) \ \ i l l usually raise the plasma
antithrombm level to approximately 120rr m α congemtally deficient
mdividual with a baselme level ot 50% (58-62) Plasma levels should
be momtored to ensuie that they remam above 80%, the admmistration
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of 60% of the initial dose at 24 h mtervals is recommended to mamtain
mhibitor levels in the normal ränge (62)
Due to the intrequent occurrence of coumann-mduced skin necrosis,
it may be advisable to take special precautions when mitiating oral anti-
coagulant treatment m a patient who is previously known or likely to
have PC deficiency Warfann should be started only when the patient is
fully hepannized and the dose of the drug should be mcreased gradual-
ly, stanmg from a relatively low level (e g , 2 mg for the first 3 days and
then m increasmg amounts of 2 to 3 mg until therapeutic anticoagula-
tion is achieved) Patients with heterozygous PC deficiency and
a history of wartann induced skin necrosis have been successfully
retreated with oral anticoagulants Here PC admmistration either in the
form of fresh frozen plasma or PC concentrate provides protection
agamst the development of recurrent skin necrosis until a stable level of
anticoagulation is achieved (63,64)
After an episode of venous thrombosis or pulmonary embohsm, pa-
tients are usually contmued on oral anticoagulants for 3 to 6 months
Recent data indicates that the nsk of recurrence is greater m patients
with permanent äs opposed to temporary nsk factors for thrombosis
(65, 66) and it is therefore appropnate that warfarm should be contm-
ued for at least 6 months at an INR of 2 0 to 3 0 in patients with
inhented thrombophilia
After 6 months of anticoagulant treatment for an acute thrombotic
event, an assessment must be made äs to the relative benefit conferred
by long-term anticoagulant therapy in preventmg future thrombo-
embohc comphcations versus the potential side-effects, cost, and m-
convemence for the patient Unfortunately there is a paucity of rehable
data regardmg the magmtude of the thrombotic nsk or the benefit of
anticoagulant treatment m patients with deficiencies of antithrombm.
PC, or PS äs these are relatively uncommon disorders Due to the high
frequency of APC-R m patients presentmg with a first episode of
venous thrombosis, rehable data is just emergmg regardmg the nsk of
recurrence (67) At this time however. only general guidehnes (rather
than rigid lecommendations) for managmg patients with the vanous
hereditary defects predisposmg to thrombosis will be proposed
Inhented Tlu ombotic Disoideis and Recommendatwns Pertaming
to Duratwn of Anticoagulant Tieatment
When a heterozygous patient with one of the hereditary thrombotic
disorders is identified. tamily studies should be conducted since
approximatelv half of their first-degree relatives will be affected
Affected asyrnptomaüc mdividuals should receive counselmg regard-
mg the imphcations of the diagnosis and advice regardmg Symptoms
that require immediate medical attention In women of child-beanng
age, oral contraceptives are generally contramdicated m view of the
mcreased thrombotic nsk associated with the use of these medications,
although individual circumstances need to be taken mto consideration
The replacement dose of estrogens that is admmistered to postmeno-
pausal women is much lower than the contraceptive dose and has not
been shown to mcrease the nsk of venous thrombosis in the general
population (68) As theie are not currently data mdicatmg that these
medications mcrease the nsk ot thrombosis m patients with a hereditary
thrombotic disoider, postmenopausal estrogen leplacement is not
absolutely contramdicated m women who have a strong mdication for
replacement therapy
All biochemicallv atteited mdividuals should be carefully evaluated
pnor to surgical, medical or obstetnc protedures that carry an mcreased
thrombotic nsk These subjects should then receive appropnate prophy-
lactic anticoagulation regimens 1t specitic concentrates are available
tor the patient's deficiency state, under some restncted circumstances
these might also be admmistered to raise the plasma levels of the pro-
tem to the normal ränge dunng the pen-operative penod
In patients with an inhented thrombotic disorder, the occurrence of
two or more spontaneously occumng thromboembohc episodes often
leads to the contmuation of oral anticoagulants for life. even though
some feel that the nsks of bleedmg could exceed those of recurrence of
thrombosis
Given that future events in an asymptomatic patient or m an individ-
ual with only one pnor thrombotic episode cannot currently be accu-
rately predicted and that there is a fimte nsk of bleedmg associated with
warfann therapy, recommendations relatmg to long-term anticoagula-
tion are best mdividuahzed at the current time (69, 70) The climcal
features that should be considered in making this decision mclude
1 Whether the thrombotic episodes were spontaneous or whether pre-
cipitatmg factors were present, e g , if a precipitatmg event such äs a
major abdominal Operation was present, it would be reasonable to
manage the patient without long-term oral anticoagulation after the
acute episode was adequately treated
2 The sex and hfestyle of the individual, e g , situations where these
factors may influence the decision-making process mclude women
of child-beanng age planmng to conceive, occupations that entail
prolonged penods of immobihzation and thereby might be associat-
ed with an mcreased nsk of thromboembohsm, jobs with higher than
average chance of trauma that might lead to thrombotic or bleedmg
comphcations
3 A history of thromboembohsm m other biochemically affected
members of the family, though marked mtra- and mter-familial
heterogeneity has been observed m the phenotypic expression of the
mhented thrombotic disorders
4 The number, Sites, and seventy of thrombosis, e g , a patient who
pieviously sustamed a massive pulmonary embolus is more likely to
receive long-term warfann than a subject who developed deep
venous thrombosis m a calf vem
Management ofPtegnancM
The management of pregnancies in women with hereditary throm-
botic disorders poses special problems (71) äs formal studies evaluat-
mg treatments and exammmg decision analyses are unavadable The
incidence ot thrombotic comphcations dunng pregnancy and the post-
partum penod appears to be greater in women with antithrombm deti-
ciency than m those with deficiencies of PC or PS (35) Recent data
also indicates that 60% of women who develop a first episode of venous
thrombosis dunng pregnancy have a diagnosis of APC-R (10) Durmg
pregnancy, adjusted-dose heparm admmistered by the subcutaneous
route is the anticoagulant of choice m many Centres because its effica-
cy and safety for the fetus are estabhshed (72) (Centres with increasmg
expenence of low MW hepanns, howe\ er, might prefer to use this class
of agent, m view of potentially simpler laboratory momtonng) Patients
with a history ot thrombotic episodes should receive treatment through-
out pregnancy, while affected women with antithrombm deficiencv
who have not yet expenenced such events should probably receive
treatment Treatment of asymptomatic women with other hereditary
thrombotic disorders should be considered on an individual basis
The dose and duration of heparm therapy m pregnancy (and mdeed
even its overall benetit) is uncertam äs uppropnately designed climcal
tnals have not been pertormed m these patient populations Patients
considered to be at high nsk should lecene tull-dose heparm by sub-
cutaneous mjection every 12 h tor the duration ot pregnancy The dose
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of hepann should be adjusted to mamtain the 6 h postinjection-APTT
l 5 times the control value In woraen considered to be at intermediate
nsk, lower doses of heparm can be used (5,000 to 10,000 units subcuta-
neously every 12 h) and therapy can be started dunng the second or
third trimester and contmued for approximately 6 weeks mto the post-
partum penod Low nsk patients can be observed closely throughout
the pregnancy with duplex ultrasound imagmg of the leg vems at regu-
lär mtervals
In women who are planning pregnancy while chronically taking oral
anticoagulants, several approaches can be taken to mmimize the nsk of
both thrombotic comphcations and warfann erabryopathy One is to
stop warfann and commence subcutaneous hepann therapy this poten-
tially exposes the patient to many months of hepann therapy and the
nsk of osteoporosis while she is trymg to conceive An approach in
women with antithrombm deficiency is to use antithrombm concen-
trates until conception This product, however, is costly and needs to be
admimstered mtravenously at frequent mtervals Fmally, warfann ther
apy could be contmued with the performance of pregnancy tests on a
frequent basis As soon äs pregnancy is diagnosed, and pnor to the sixth
week of gestation, oral anticoagulants must be discontmued and hepar-
m therapy mitiated Though the nsk of warfann embryopathy
appears to be quite small dunng the first six weeks of pregnancy (73),
even the small nsk of this complication makes this the least preferable
of the three approaches
Coumann-mduced Skm Necrosis and Neonatal Purpurn fulmmans
A clear association has been estabhshed between the rare complica-
tion of coumann-induced skm necrosis and hereditary PC deficiency
(63,74) About a third of patients with coumann-mduced skm necrosis
will prove to have hereditary PC deficiency (75) This complication has
also been descnbed m a patient with heterozygous PS deficiency (76)
As coumann-induced skm necrosis is a rare complication, therapy has
been guided pnmanly by knowledge regardmg its pathogenesis The
diagnosis should be suspected m patients with painful, red skm lesions
developing withm a few days after the Initiation of the drug and imme-
diate Intervention is required to prevent rapid progression and reduce
comphcations Therapy should consist of immediate discontmuaüon of
warfann, admmistration of Vitamin K, and mfusion of hepann at thera-
peuüc doses Lesions, however, have been reported to progress despite
adequate anticoagulation with hepann In patients with hereditary PC
deficiency, the admmistration of a source of PC should be senously
considered, and it may also be appropnate m other patients with warfar
in-mduced skm necrosis äs they mvanably have reduced plasma levels
of functional PC when the skm lesions first appear Fresh frozen
plasma has been used, but improved results can be expected with the
admmistration of a highly punfied PC concentrate, which facilitates the
rapid and complete normahzation of plasma PC levels (77)
The management of neonatal purpura fulmmans m association with
homozygous or doubly heterozygous PC deficiency is more complicat-
ed and hepann therapy äs well äs antiplatelet agents have not been
shown to be effective (44,78-80) The admmistration of a source of PC
appears to be cntical m the initial treatment of these patients Fresh
frozen plasma has been used with success to treat these mfants How-
ever, the half-life of PC m the circulation is only about 6 to 12 hours
(81,82), and the admimstration of plasma on a frequent basis is limited
by the development of hyperprotememia, hypertension loss of venous
access, and the potential for exposure to mfectious viral agents A high-
ly punfied concentrate of PC has been developed and is efficacious m
treatmg neonatal purpura tulminans (83) Wartarm has been admims-
tered to these mfants without the redevelopment of skm necrosis dunng
the phased withdrawal of fresh frozen plasma mfusions (44,80,84-86),
and this medication has been used chronically to control the thrombot-
ic diathesis A 20 month old child with hver failure and homozygous
PC deficiency has undergone successful hver transplantation which
normalized his PC levels and resolved the thrombotic diathesis (87)
Neonatal purpura fulmmans has been descnbed in association with
homozygous PS deficiency (88, 89)
Prenatal Diagnosis in Inhented Thrombophilia
Prenatal diagnosis can only be considered appropnate m possible
cases of severe thrombophiha where the fetus is expected to be homo-
zygous or compound heterozygous for mhibitor deficiency Only m a
few mstances has prenatal diagnosis been performed, m attempts to
avoid severe thrombophiha The initial procedure used was fetal blood
samplmg by cordocentesis dunng the 19th week of gestation m a
woman who had previously delivered two newborns who died of
massive thrombosis and purpura fulmmans due to homozygous PC
deficiency (90) At this stage of gestation the mean level of PC antigen
is about 10 U/dl (90-92), and thus, care should be taken m distmguish-
mg between results consistent with heterozygosity with a PC level of
about 5 U/dl and homozygosity In two reports the mean level of fiee
PS antigen at 15-23 weeks of normal gestation was 27 and 38 U/dl,
respectively (91, 92), and hence the diagnosis of homozygous PS defi-
ciency by fetal blood samplmg should be easier than the diagnosis of
severe PC deticiency Such a procedure has not so far been camed out
m cases of suspected severe PS deficiency
A more direct and precise approach to prenatal diagnosis of severe
deficiencies of PC, PS and antithrombm depends pnmanly on the iden
tification of the mutaüon or mutations responsible for the disease m the
proband and on devismg an easy method for its detection, i e , poly-
merase cham reaction and restnction analysis or Southern analysis Such
work can be performed m highly speciahzed centers that have a partic
ular mterest m this issue For Identification of the mutaüon causmg PC
deficiency a scannmg method was devised usmg denaturant gradient
gel electrophoresis (DGGE) of 13 PCR amphfied fragments that cover
exon I and most of the PC codmg regions (93) A sirmlar approach was
also used for detection of mutations causmg PS deficiency (94) Once
these prerequisites have been met, prenatal diagnosis can be piovided
dunng the 9-10th week of gestation by chonomc vülus samplmg and
DNA analysis Such an approach was recently used m a family affect-
ed by severe PC deficiency (95) and also m a tamily with antithrombm
deficiency type IIHBS, m which the fetus was potentially homozygous
for a 99 Leu to Phe Substitution and heterozygous for factor V 506Arg
to Gin (96) Prenatal exclusion of a severe thrombophiha may also be
camed out by mdirect restnction fragment length polymorphism
(RFLP) trackmg Such a procedure was used m a family m which a
previous mfant died of bilateral renal vem thrombosis and both parents
were found to be heterozygotes for PS deficiency (97)
linherited Thrombophiha in the Developing Countnes
The prevalence and morbidity of thrombophiha in different geo-
graphic regions of the world may be difterent because of genetic racial
differences or because the phenotypic expression of the disease is al-
tered by environmental factors While several studies on mhented
thrombophiha have been published, these should be mterpreted with
caution, due to many problems mvolved m the execution ot the work
For example, there are concerns with quahtv control ot laboratory
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assays, with objective diagnosis of thrombosis and with study design
Furthermore, no large epidemiological studies on groups such äs blood
donors have been performed m developmg countnes and there are
therefore no reasonable estimates of the prevalence of the mhibitor
deficiencies
Despite these reservations, a number of published reports have
attempted to address the issues of frequency of venous thrombosis
followmg surgery (98-102) and of hereditary throbophiha (103-105)
The avaüable data suggests that the prevalence of deep venous throm-
bosis may be less m the developmg than m the developed countnes
However, there are suggestions that patients who do get venous
thrombosis are more hkely to have an underlymg mhibitor deficiency
Another potentially mterestmg aspect is that early onset of stroke may
be associated with mhibitor dehciency (106) Further work is clearly
required to consohdate these vanous observations
Conclusions
1 At the present time, mutations in four genes are clearly Imked to
increased nsk for venous thromboembolism Many discrete mutations
cause deficiencies of antithrombm, PC and PS that dimimsh the capac-
ity to balance procoagulant activity One specific mutation m factor V
506Arg to Gin has a similar impact by rendermg this procoagulant
factor resistant to proteolytic degradation With these four estabhshed
nsk factors for thrombosis, roughly 50% of the familial thrombophihas
can be explamed Apparently a number of other genetic nsk factors so
far has escaped detection It is however unhkely that these will be found
among deficiencies of plasminogen, heparm cofactor II, tissue factor
pathways mhibitor or ß2 glycoprotem I Other candidates will need
further evaluation (for mstance, dysfibnnogenemia thrombomodulm
defects and mhented hyperhomocystememia) It is mcreasmgly appar-
ent that co-mhentance of more than one relatively mild thrombophilic
nsk factor causes more severe clmical expression
2 Increasmgly, attempts are bemg made to assign a magmtude to
genetic and acquired nsk factors The nsks estimates that have been
found m various studies depend heavily on the way the subjects for
those studies were selected and do not necessanly apply to mdividuals
selected differently In particular, results from studies among selected
famihes with stnking thrombophiha are probably overestimatmg the
nsk when apphed to mdividuals who were found because of a smgle
thrombotic event The most strmgent selection cntena have been used
to ascertam farmlies with the rare abnormahties (PC, PS or antithrom-
bm), which more readily explams the differences found m family stud-
ies on these disorders äs compared to APC-R than a true difference m
seventy Fmally, when gene-gene and gene-environment mteractions
are required to bring about thrombosis, there will be differences withm
famihes äs much äs between famihes
3 Laboratory evaluation of thrombophiha should mvolve the use of
assays with highest possible sensitivity and specificity for the genetic
defect that is to be detected Assays can be of immunological and func
tional nature, m the case of immunological assays it should be realized
that cases with truly functional defective protems may not be detected
A practically useful approach should be taken and the selection of
analytical procedures should be govemed by the aim of the mvestiga
tion äs well äs of locally determmed tactors such äs prevalence ot the
genetic defects to be detected and availabihty ot techmcal suppoit
Based on avaüable scientific Information, the laboiatory evaluation
should mclude measurements ot PC, total and tree PS, antithrombm
and a functional APC R test which is sensitive and specific for the pres-
ence of the tactor V 506 Gin allele
In the case of PC, assays which are based on its activation with the
PC activator Protac and measurements of the active enzyme with
synthetic Substrate, fulfil required quality cntena At present no func-
tional PS assays can be recommended for general screenmg of throm-
bophilic patients Immunological assavs of total äs well äs ot free PS
are recommended Recently published results mdicate free PS to be the
best marker for genetically determmed PS deficiency but further
studies are required before a recommendation only to measure free PS
can be made The functional assays for antithrombm which are based
on hepann stimulated Inhibition of factor Xa are recommended for
screenmg of thrombophilic patients For initial screenmg of APC-R,
functional tests are recommended The test can be impro\ed by dilutmg
the patient plasma m FV-deficient plasma As assays for PC and PS
have distmctly lower sensitivity and specificity for the presence of
mhented deficiency durmg the acute thrombotic epidsode and oral anti-
coagulation, it is at present recommended to perform the laboratory
mvesügation for these components after discontmuation of the therapy
4 The clmical mamfestations of the defects of naturally-occumng
anticoagulant Systems (antithrombm, PS and PC deficiencies, APC R)
are similar In heterozygotes, typical mamfestations are those of venous
thromboembolism, such äs deep-vem thrombosis of the legs, pulmonary
embohsm and superficial thrombophlebitis Visceral and cerebral vein
thrombosis are rarer but quite typical for mhented thrombophiha Pa-
tients with homozygous defects have usuallv more severe clmical mam
festations with an earlier age of onset Some mamfestations are quite typ-
ical for homozygous defects, such äs skm necrosis and widespread neo
natal thrombosis m PC and PS deficiencies There are prehminaiy data
suggesting that some homozygous defects (antithrombm type IIHBS de-
ficiency) may be also associated with an increased nsk for artenal throm
bosis m the young but moie data on this and other homozygous deficien-
cies are warranted to establish am relationship with artenal disease
5 When a symptomatic patient with mhented thrombophiha due
to a known genetic defect is identified family studies should be
conducted smce approximately half ot their first-degree relatives will
be affected Asymptomatic mdmduals who carry the genetic defect
should receive counsellmg regaidmg the imphcations of the diagnosis
and Symptoms that reqmre medical attention In general, the manage
ment of symptomatic mdividuals with the genetic defect is similar to
that for symptomatic patients without an identifiable genetic defect An
exception is patients with neonatal purpura fulmmans m association
with homozygous or doubly heterozygous PC deficiency m whom the
admimstration of a source of PC is cntical m initial treatment Given
that future thrombotic events m patients with mhented thrombophiha
cannot be accurately predicted and there is a fimte nsk of bleedmg
associated with anticoagulant therapy recommendations relatmg to
long-term treatment are best mdividuahzed at the current time
6 Once an mdividual is defmed äs bemg affected by hereditary
thrombophiha äs many family members äs possible are exammed for
the particulai defect detected m the proband and a pedigree is construct-
ed Familv members who are found to be affected are counselled about
the nsk of thrombosis An evaluation of the potential nsk of birth of
severely atfected newborns is usually carned out m famihes in which
mteimarriage is practised, and consequemlv counsellmg, extensive
camer detection and prenatal diagnosis is planned and executed
The target tamihes for prenatal diagnosis ot hereditary thrombophil-
las are those famihes that had already been atflicted by mfants with
seveie thrombosis due to homozygositv 01 compound heterozygosity
for PC PS or antithrombm detiueni\ äs well äs those famihes
mentioned above In these target tamihes an attempt is made to detect
the responsible mutation(s), and to de\ise α simple method for their
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detection, e g , PCR and restnction analysis or Southern analysis This
is follovved by an extensive study of family members m the child-bear-
ing age for camership and äs a consequence counselhng is provided
Prenatal diagnosis is then based on DNA obtamed by chonomc villus
sampling or amniocentesis
In mstances m which the mutation cannot be identified, specific
RFLP trackmg m family members and eventually in fetal DNA is an
alternative approach In still other mstances of PC or PS deficiency
tetal blood sampling at 18-22 weeks of gestation is an Option smce data
on the levels ot these components in normal fetuses are available For
antithrombm such values are unavailable and thus at present fetal blood
sampling for affected famihes cannot be offered, unless the specific
mutation has been identified
7 Deep vem thiombosis and pulmonary embohsm have a lower
mcidence m the developing world when compared to the West, and this
may be due to a combmation of racial and environmental factors There
are hmited studies with complete laboratory evaluation on inhented
thrombophiha from the developing countnes It appears that there is a
higher Chance of finding an underlymg genetic defect (PC PS and anti
thiombm deticiency) m patients with thrombosis m the developing
world Prelimmary data on APC-R suggests that this defect is rare m
Asians, Afncans and Chinese
Recommendations
1 Recent reports m the hteratuie support the hypothesis that famihal
thrombophiha is a multiple gene disorder and that the penetrance of
the disease is higher m camers of multiple gene defects In relation
to this it ii> to be expected that prophylactic and therapeutic meas
ures need to be adjusted to the number of mdependent nsk factors
present in an individual Therefore efforts should be intensified to
identify those genetic nsk factors that so far have escaped detection,
so that these can be mcluded m diagnostic screenmg procedures
2 Guidelmes need to be developed for the use of specific laboratory
tests m screenmg procedures aimmg at the Identification of individ-
uals who carry a genetic nsk factor for venous thrombosis
3 Given the large number of patients that must be followed to detect
new abnormalities, collaborative international mvestigations with
standardized recruitment protocols should be encouraged
4 More Information Imking genetic causes of hvperhomocystememia
to venous thromboembohsm is necessary
5 An estimate of the prevalence of PS deficiency m the population
would help evaluate its relative nsk
6 More specific recommendations need to be developed for the
classification of hereditary PS deficiencv Within this context it
needs to be established whether so called type III PS deficiency is
an mdependent nsk factor for venous thrombosis or a different phe-
notype of type I PS deficiency
7 As recent data suggest that measuiement ot free PS may be more
valuable than total PS assays toi the diagnosis of PS deficiency, it
is recommended that studies are pertormed which evaluate the
performance of different methods tor determmation of free PS
8 General screenmg of the population tor genetic defects of PC, PS
and antithrombm can at present not be lecommended mainly based
on the low prevalence of these detects m the population and on
the low predictive value of a positive test It is recommended that
studies are performed which address the question whether general
screenmg for APC R (FV 506 Gin allele) e g betoie oral contra-
ception, surgery or hospitahzation is beneticial toi the decision on
therapeutic and prophylaUic legimes
9 Further climcal studies should be orgamzed to evaluate whether
detects causmg mhented thrombophiha are a cause of or contnbute
to artenal thrombosis
10 Heterozygous deficiencies of PC, PS or antithrombm should not be
the target ot prenatal diagnosis In view of the very low expected
trequency of the severe homozygous or compound heterozygous
defects m PC, PS and antithrombm m the general population it is
not recommended to carry out population screenmg for camership
11 It would be preferable to establish reference centres where work
up of the mutations and DNA based prenatal diagnosis can be
performed in cases with severe defects
12 It is necessary to obtam accurate data on the frequency and impact
of thrombophiha in the developing world In order to do this mdi-
vidual laboratones should be identified m different regions and
these should develop the necessary expertise to screen for and
document the genetic defect responsible m association with WHO
Collaboratmg Centres
13 For the present screenmg should be done on all patients with venous
thromboembohsm m the context of a study to determme the per-
centage of patients with hereditary thrombophiha m the developing
world where thrombotic disorders m general appear to have a low
prevalence Family studies should be done m all patients m whom a
genetic defect is documented
14 Smce facilities for screenmg may be available only m reference
centers treatment should be mitiated without delay where appropn
ate and tests performed m the reference center after anticoagulants
have been discontmued
15 Data on the thrombotic nsk in patients and asymptomatic family
membeis with thrombophiha should be collected to determme
whether the nsk profile is different m the developing world
16 Careful documentation of the nsk of hemorrhage on anticoagulants
is necessary m order to determme the nsk benefit ratio of therapeu-
tic Intervention in patients with thrombophiha
17 Recommendations for screenmg for hereditary thrombophiha at a
national level m health care Services can be made only after
adequate data on the epidemiology, nsk of thrombosis and lesult of
therapeutic Intervention is available
18 Smce there is a higher mcidence of stroke m the young m the
developing world this population needs to be studied in order to
determme the number of patients who have thrombophiha äs the
underlymg cause
19 In order to mcrease awareness of mhented thrombophiha m devel-
oped and developing countnes, it is proposed, m cooperation with
the ISTH, to select two centres for designation äs WHO Collaborat-
mg Centres to improve diagnosis, climcal recognition and treatment
of related thrombosis These Centres will serve äs reference centres
for the appropnate WHO Regions and will improve education of
both health professionals and the general pubhc
20 The next meetmg of WHO/ISTH experts should be orgamzed at
one of the proposed centres for designation äs a WHO Collaborat-
mg Centre, and focus on the climcal problems ot mhented thrombo-
phiha A traming course on the diagnosis for thiombophilia for
local doctois and invited participants from countnes withm the
WHO Region should also be foieseen at the samc time
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